RxDoctor Payments Data

Brooke Gregory

Family · Loogootee, INNPI 1205474921

Payments from drug & device makers

$1,630in general payments, 2019–2025

Across 100 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$362
  • AbbVie$230
  • GSK$138
  • Novo Nordisk$87
  • Amgen$83
  • AstraZeneca$77
  • plus $653 from 22 others

What the payments were for

  • Food & beverage$1,61999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,630 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,410
Albuterol Sulfate HfaAlbuterol Sulfate53$1,159
Gabapentin40$456
Metformin Hcl35$305
Pravastatin Sodium16$299
Omeprazole31$258
Levothyroxine Sodium37$247
Fluticasone Propionate11$224
Lisinopril52$221
Losartan Potassium25$204
Atorvastatin Calcium26$196
Escitalopram Oxalate18$165
Mirtazapine14$159
Cyclobenzaprine Hcl14$151
Mupirocin14$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$138$9,41011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Loogootee

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →